Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
This trial is active, not recruiting.
|Condition||chronic lymphocytic leukemia|
|Sponsor||Dartmouth-Hitchcock Medical Center|
|Collaborator||American Cancer Society, Inc.|
|Start date||October 2011|
|End date||December 2016|
|Trial size||30 participants|
|Trial identifier||NCT01460238, D11065|
The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.
No intervention. Each patient will have blood drawn at a standard of care venipuncture.
LPL Protein Expression
time frame: 1 year
Fatty acid acquisition and synthesis
time frame: 1 year
Male or female participants at least 18 years old.
- Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
- Patients undergoing routine blood draws as part of their ongoing follow up for CLL
- 18 years or older
- Ability to provide consent in English
- Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.
- Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
- other hematologic malignancy or other disease process within the past 6 months are excluded.
|Official title||Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia|
|Principal investigator||Frederick Lansigan, MD|
|Description||The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL expression correlates with a more aggressive type of CLL. The investigators propose that LPL protein expression on CLL cells is prognostic and that LPL and other proteins involved in fatty acid metabolism are critical for CLL cells to survive.|
Call for more information